Heterozygous BRAF variants (~ 75%) constitute the majority of CFC cases, whereas variants in the MAP2K1 or MAP2K2 genes (~ 25%) and KRAS (< 2%) also cause CFC. This evidence concerns the gene MAP2K2 and cardiofaciocutaneous syndrome.